These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38264861)

  • 21. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
    Coleman CI; Dobesh PP; Danese S; Ulloa J; Lovelace B
    Future Cardiol; 2021 Jan; 17(1):127-135. PubMed ID: 32618210
    [No Abstract]   [Full Text] [Related]  

  • 23. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
    Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
    Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Andexanet alfa for the reversal of factor Xa inhibitors.
    Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
    Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
    Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
    J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
    Fanikos J; Goldstein JN; Lovelace B; Beaubrun AC; Blissett RS; Aragão F
    J Med Econ; 2022; 25(1):309-320. PubMed ID: 35168455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
    Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
    J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
    Klok FA; Huisman MV
    Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report.
    Jenniches D; Kerns AF; DelBianco J; Stripp MP; Philp AS
    Am J Health Syst Pharm; 2023 Nov; 80(23):1722-1728. PubMed ID: 37688311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
    Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
    J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
    Lipari L; Yang S; Milligan B; Blunck J
    Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
    Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ;
    Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
    White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
    Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage.
    Gerner ST; Kuramatsu JB; Sembill JA; Sprügel MI; Endres M; Haeusler KG; Vajkoczy P; Ringleb PA; Purrucker J; Rizos T; Erbguth F; Schellinger PD; Fink GR; Stetefeld H; Schneider H; Neugebauer H; Röther J; Claßen J; Michalski D; Dörfler A; Schwab S; Huttner HB;
    Ann Neurol; 2018 Jan; 83(1):186-196. PubMed ID: 29314216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.